Idera Pharmaceuticals Inc (IDRA)
0.4578
-0.02 (-4.49%)
USD |
NASDAQ |
Aug 12, 16:00
0.451
-0.01 (-1.49%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.29M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.38% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.149 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.56% |
News
Headline
Wire
Time (ET)
PR Newswire
05/17 10:30
MT Newswires
05/17 09:34
SA Breaking News
05/17 08:39
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/08/2022* | -- | Results | Q3 2022 | -- | -0.13 | -- | |
| 11/08/2021 | -- | Results | Q3 2021 | -0.11 | -0.12 | 7.80% | |
| 08/09/2021 | -- | Results | Q2 2021 | -0.13 | -0.11 | -15.91% | |
| 04/29/2021 | -- | Results | Q1 2021 | -0.24 | -0.22 | -9.09% | |
| 03/01/2021 | -- | Results | Q4 2020 | -0.22 | -0.21 | -4.76% | |
| 10/29/2020 | -- | Results | Q3 2020 | -0.21 | -0.23 | 8.70% | |
| 08/04/2020 | -- | Results | Q2 2020 | -0.24 | -0.40 | 40.00% | |
| 04/30/2020 | -- | Results | Q1 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. |
| URL | https://www.iderapharma.com |
| Investor Relations URL | http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-irhome |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 08, 2022 (est.) |
| Last Earnings Release | Nov. 08, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 12, 2022.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 19.51M |
| Net Income (TTM) | -19.57M |
| Total Assets (Quarterly) | 26.31M |
| Total Liabilities (Quarterly) | 5.174M |
| Shareholders Equity (Quarterly) | 21.13M |
| Cash from Operations (TTM) | -16.84M |
| Cash from Investing (TTM) | 0.00 |
| Cash from Financing (TTM) | 0.73M |
Ratings
Profile
Edit
| Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. |
| URL | https://www.iderapharma.com |
| Investor Relations URL | http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-irhome |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 08, 2022 (est.) |
| Last Earnings Release | Nov. 08, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| IDRA Tweets |